These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37858287)

  • 1. BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpoints.
    Bi D; Liu M; Lin J; Liu R
    Stat Med; 2023 Dec; 42(30):5708-5722. PubMed ID: 37858287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trials.
    Hupf B; Bunn V; Lin J; Dong C
    Stat Med; 2021 Jun; 40(14):3385-3399. PubMed ID: 33851441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propensity-score-based meta-analytic predictive prior for incorporating real-world and historical data.
    Liu M; Bunn V; Hupf B; Lin J; Lin J
    Stat Med; 2021 Sep; 40(22):4794-4808. PubMed ID: 34126656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bayesian group sequential design for randomized biosimilar clinical trials with adaptive information borrowing from historical data.
    Zhang W; Pan Z; Yuan Y
    J Biopharm Stat; 2022 May; 32(3):359-372. PubMed ID: 35679137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal timing for an accelerated interim futility analysis incorporating real world data.
    Haine LMF; Murray TA; Koopmeiners JS
    Contemp Clin Trials; 2024 May; 140():107489. PubMed ID: 38461938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian adaptive randomization design incorporating propensity score-matched historical controls.
    Sawamoto R; Oba K; Matsuyama Y
    Pharm Stat; 2022 Sep; 21(5):1074-1089. PubMed ID: 35278032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simulating and reporting frequentist operating characteristics of clinical trials that borrow external information: Towards a fair comparison in case of one-arm and hybrid control two-arm trials.
    Kopp-Schneider A; Wiesenfarth M; Held L; Calderazzo S
    Pharm Stat; 2024; 23(1):4-19. PubMed ID: 37632266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian borrowing from historical control data in a vaccine efficacy trial.
    Peng L; Jin J; Chambonneau L; Zhao X; Zhang J
    Pharm Stat; 2023; 22(5):815-835. PubMed ID: 37226586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials.
    Jiang L; Thall PF; Yan F; Kopetz S; Yuan Y
    Clin Trials; 2023 Oct; 20(5):486-496. PubMed ID: 37313712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size calculation for clinical trials analyzed with the meta-analytic-predictive approach.
    Qi H; Rizopoulos D; van Rosmalen J
    Res Synth Methods; 2023 May; 14(3):396-413. PubMed ID: 36625478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling.
    Wei W; Blaha O; Esserman D; Zelterman D; Kane M; Liu R; Lin J
    Stat Med; 2024 May; 43(12):2439-2451. PubMed ID: 38594809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel power prior approach for borrowing historical control data in clinical trials.
    Shi Y; Li W; Liu GF
    Stat Methods Med Res; 2023 Mar; 32(3):493-508. PubMed ID: 36601652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robust meta-analytic-predictive priors in clinical trials with historical control information.
    Schmidli H; Gsteiger S; Roychoudhury S; O'Hagan A; Spiegelhalter D; Neuenschwander B
    Biometrics; 2014 Dec; 70(4):1023-32. PubMed ID: 25355546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian adaptive design for covariate-adaptive historical control information borrowing.
    Jin H; Kim MO; Scheffler A; Jiang F
    Stat Med; 2023 Dec; 42(29):5338-5352. PubMed ID: 37750361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical appraisal of Bayesian dynamic borrowing from an imperfectly commensurate historical control.
    Harun N; Liu C; Kim MO
    Pharm Stat; 2020 Sep; 19(5):613-625. PubMed ID: 32185886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs.
    Smith CL; Thomas Z; Enas N; Thorn K; Lahn M; Benhadji K; Cleverly A
    Pharm Stat; 2020 May; 19(3):276-290. PubMed ID: 31903699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian clinical trial design using historical data that inform the treatment effect.
    Psioda MA; Ibrahim JG
    Biostatistics; 2019 Jul; 20(3):400-415. PubMed ID: 29547966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alone, together: On the benefits of Bayesian borrowing in a meta-analytic setting.
    Harari O; Soltanifar M; Verhoek A; Heeg B
    Pharm Stat; 2023; 22(5):903-920. PubMed ID: 37321565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using horseshoe prior for incorporating multiple historical control data in randomized controlled trials.
    Ohigashi T; Maruo K; Sozu T; Gosho M
    Stat Methods Med Res; 2022 Jul; 31(7):1392-1404. PubMed ID: 35379046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian sequential meta-analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program.
    Chen MH; Ibrahim JG; Amy Xia H; Liu T; Hennessey V
    Stat Med; 2014 Apr; 33(9):1600-18. PubMed ID: 24343859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.